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Abstract: The release of therapeutic drugs from the surface of implantable devices is instrumental 
for the reduction of medical costs and toxicity associated with systemic administration. In this 
study we demonstrate the triblock copolymer-mediated deposition and release of multiple thera-
peutics from a single thin ﬁ  lm at the air-water interface via Langmuir–Blodgett deposition. The 
dual drug elution of dexamethasone (Dex) and doxorubicin hydrochloride (Dox) from the thin 
ﬁ  lm is measured by response in the RAW 264.7 murine macrophage cell line. The integrated 
hydrophilic and hydrophobic components of the polymer structure allows for the creation of 
hybrids of the copolymer and the hydrophobic Dex and the hydrophilic Dox. Conﬁ  rmation of 
drug release and functionality was demonstrated via suppression of the interleukin 6 (IL-6) and 
tumor necrosis factor alpha (TNFα) inﬂ  ammatory cytokines (Dex), as well as TUNEL staining 
and DNA fragmentation analysis (Dox). The inherent biocompatibility of the copolymeric mate-
rial is further demonstrated by the lack of inﬂ  ammation and apoptosis induction in cells grown 
on the copolymer ﬁ  lms. Thus a layer-by-layer anchored deposition of an anti-inﬂ  ammatory and 
chemotherapeutic functionalized copolymer ﬁ  lm is able to localize drug dosage to the surface 
of a medical device, all with an innate material thickness of 4 nm per layer.
Keywords: co-elution, combinatorial therapy, nanomedicine, drug delivery, chemotherapy, 
inﬂ  ammation
Introduction
The application of therapeutic drugs to a patient can lead to numerous complications. 
Most anti-cancer chemotherapies lack cellular speciﬁ  city, thus systemic administration 
inevitably causes adverse reactions in patients (Sridhar et al 1992; Gerweck et al 1999; 
Wang et al 1999; Kimura et al 2000; Kang et al 2002; Olson et al 2003) through the 
indiscriminate induction of cell death (Arola et al 2000; Kotamraju et al 2000; Wang 
et al 2004; Eom et al 2005; Hou et al 2005) of cancerous and noncancerous tissues. 
Likewise, systemically administered anti-inﬂ  ammatory steroids have been shown to 
interfere with other treatments. For example, the administration of glucocorticoid anti-
inﬂ  ammatories used to treat inﬂ  ammatory conditions in cells can interfere with the 
progression of apoptosis by various anti-cancer chemotherapies, including paclitaxel and 
doxorubicin (Moran et al 2000; Mikosz et al 2001; Wu et al 2004). The intersection of 
nanomaterials and medicine has generated platform technologies incorporating various 
methodologies for ﬁ  lm-based drug release and particle based systemic drug administra-
tion and circulation. Nanoparticles engineered to contain targeting elements can produce 
a desired response in cells that present upregulated markers that are indicative of the 
targeted condition (eg, cancerous, diseased). Nanoparticle based therapeutic delivery 
systems include diamond-based materials (Chen et al 2007; Huang et al 2007, 2008), 
metallic nanoparticles (Oishi et al 2006; Rosi et al 2006), and functionalized micelles and International Journal of Nanomedicine 2008:3(4) 426
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liposomes (Yoo et al 2001, 2004; Greish et al 2004). Film-based 
local-release modalities have further been employed for drug 
therapy which generate a concentrated response at the site of 
implantation and do not rely on systemic drug transport. These 
thin ﬁ  lm technologies include coatings to protect implants 
against breakdown/degradation through inﬂ  ammatory immune 
responses (Ariga et al 2006; Pierstorff and Ho 2007; Chow 
et al 2008). Due to the localized and directed nature of this ﬁ  lm 
based therapy, it is a platform through which a wide variety of 
clinical conditions can be targeted.
Previously, we have demonstrated the use of polymethy-
loxazoline–polydimethylsiloxane–polymethyloxazoline 
(PMOXA–PDMS–PMOXA) block copolymer membranes 
for harnessing and releasing active anti-inﬂ  ammatory and anti-
cancer therapeutics (Chow et al 2008; Pierstorff et al 2008). This 
copolymer contains both hydrophilic and hydrophilic blocks 
which allows for the formation of copolymer-drug hybrids that 
incorporate therapeutics of virtually any type regardless of its 
hydrophilic or hydrophobic characteristics (Nardin et al 2000, 
2001; Ho et al 2003, 2004). The polymer has also been shown to 
be biocompatible and is only 4 nm thick, making it noninvasive 
and an ideal candidate for a ﬁ  lm based drug eluting platform for 
medical devices. This study has combined the beneﬁ  ts of thin 
ﬁ  lm polymers with localized drug delivery to fabricate a block 
copolymer nanoﬁ  lm capable of eluting multiple therapeutics 
from a single device (Figure 1). These include dexamethasone 
(Dex), a steroid based anti-inﬂ  ammatory and doxorubicin 
hydrochloride (Dox), an anti-cancer therapeutic that induces 
cell death via apoptosis. Surface pressure isotherms were used 
to conﬁ  rm ﬁ  lm formation and drug mixing, and quantitative 
reverse transcriptase-polymerase chain reaction (RT-PCR), 
TUNEL-based cell staining, and DNA fragmentation studies 
were performed to ascertain drug release and function. Thus a 
multifunctional thin ﬁ  lm coating to address multiple conditions 
simultaneously was created.
Materials and methods
Raw 264.7 murine macrophage culture
RAW 264.7 (ATCC) murine macrophage cells were cultured 
in 1 × DMEM containing 10% fetal bovine serum (FBS) and 
Doxorubicin
Dexamethasone
Copolymer
   Thin Film
Glass Slide
Multi-Drug Eluting Copolymer Thin Film
Figure 1 The copolymer-mediated sequestering and integration of multiple therapeutics into a single thin ﬁ  lm is shown. Langmuir-Blodgett was used to deposit drug containing 
triblock copolymer ﬁ  lms that can maintain drug incorporation for localized release. Combinatorial therapy at the surface of the material–tissue interface can provide signiﬁ  cantly 
enhanced treatment produced by a noninvasive nanoscale platform. Copyright © 2008.   Adapted from Pierstorff E, Krucoff M, Ho D. 2008. Apoptosis induction and attenuation 
of inﬂ  ammatory gene expression in murine macrophages via multitherapeutic nanomembranes. Nanotechnology, 19:265103–12.International Journal of Nanomedicine 2008:3(4) 427
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1% penicillin/streptomycin at 37 °C with 5% carbon dioxide. 
Cells were plated onto the fabricated substrate slides (glass, 
polymer only, or polymer–drug) and grown for the indicated 
time points. For inﬂ  ammation studies, 5 ng/mL lipopolysac-
charide (LPS) (Sigma, St. Louis, MO) was added for the 
last 4 hours of incubation followed by cell harvesting. For 
apoptosis studies, an additional 10% of FBS was added to the 
cell culture every 24 hours to prevent serum starvation.
Anti-inﬂ  ammatory and chemotherapeutic 
Langmuir–Blodgett ﬁ  lm fabrication
Langmuir–Blodgett (LB) ﬁ  lms were fabricated using a KSV 
2000 Standard Langmuir Trough with a Teﬂ  on® base, Delrin 
barriers, platinum Wilhemy pressure sensor, and a subphase of 
water. The entire trough was covered with a plastic case with 
an integrated door to enable manual manipulation/cleaning of 
the trough. The base was cleaned with multiple washings with 
methanol and nanopure water using a lint free wipe to ensure 
trough cleanliness and the trough was then ﬁ  lled with nanopure 
water. The Wilhemy platinum pressure sensing plate (stored 
in MeOH) was thoroughly rinsed using nanopure water and 
heat-sterilized just before use. The pressure sensor was zeroed 
immediately prior to ﬁ  lm deposition or isotherm reading.
Dexamethasone (Sigma) was dissolved in 100% ethanol to a 
concentration of 5 mg/ml and Doxorubicin (US Pharmacopeia, 
Rockville, MD) was dissolved in nanopure water to a 
concentration of 2.5 mg/ml. The drugs (60 μl dexamethasone, 
400 μl doxorubicin) were then added to an interfacial pre-formed 
20 mN/m copolymer ﬁ  lm (Polymer Source, Montreal, QU, Can-
ada) and changes in surface pressure were monitored to conﬁ  rm 
drug presence at the air-water interface. After 30 minutes of 
allowing the ﬁ  lm to reach equilibrium, compressions were 
performed at a rate of 1mm/min to a maximum pressure of 
25 mN/m for LB deposition onto glass slides (25 mm  ×  75 mm) at 
a rate of 1mm/min. Films were compressed to 50 mN/m until 
collapse for Langmuir ﬁ  lm characterization of ﬁ  lm properties. 
Three layers of drug-functionalized polymer were deposited 
and used for the studies.
Polymer–dexamethasone-driven 
suppression of inﬂ  ammatory gene 
expression
RAW 264.7 cells were plated onto the fabricated sub-
strate slides (glass, polymer only, or polymer–drug) and 
grown for 24 hours at 37 °C with 5% carbon dioxide. Cells 
were stimulated with LPS for 4 hours, followed by cell 
harvesting. RT-PCR was performed for gene expression 
analysis to reﬂ  ect ﬁ  lm functionality as described previously 
(Pierstorff et al 2008). Brieﬂ  y, TRIzol reagent (Invitro-
gen, Carlsbad, CA) was added to each sample to collect 
the RNA. Subsequent RNA isolation was performed 
according to the manufacturer’s protocol, RNA was 
converted to cDNA using the I-script enzyme (Bio-Rad, 
Hercules, CA). Real time PCR analysis (Bio-Rad) was 
performed monitoring the expression of the genes interleukin 
6 (IL-6) and tumor necrosis factor alpha (TNFα) at each 
time point. Control primers (β-actin) were used to normalize 
for cDNA concentration variation. Primer sequences 
utilized are as follows: TNFα: 5’-GGTGCCTATGTCT-
CAGCCTCTT-3’ and 5’-CGATCACCCCGAAGTTCAGT1, 
IL-6: 5’-CACAGAGGATAC-CACTCCCAACA-3’ 
and 5’ TCCACGATTTCCCAGAGAACA-3’, β-actin: 
5’-TGGAATCCTGTGGCATCCATGAAAC-3’ and 
5’-TAAAACGCAGCTCAGTAACAGTCCG-3’.
DNA fragmentation assay 
for chemotherapeutic nanoﬁ  lms
RAW 264.7 cells were plated onto the fabricated substrate 
slides (glass, polymer only, or polymer–drug) and grown for 
67 hours at 37 °C with 5% carbon dioxide. Cultures were 
supplemented with an additional 10% FBS every 24 hours 
to prevent serum starvation. Cellular DNA was puriﬁ  ed as 
described previously (Huang et al 2007). Brieﬂ  y, cells were 
lysed in 500 μL lysis buffer (10 mM Tris-HCl, pH 8.0, 10 mM 
EDTA, 1% Triton X-100) follwed by 30-minute incubations 
with RNase A and proteinase K, separately. After phenol 
chloroform extraction, nuclear DNA was precipitated in 
isopropyl alcohol, washed in 70% ethanol, and resuspended 
in DEPC water. Samples were electrophoresed on 0.8% 
agarose gel, and stained with ethidium bromide.
Confocal microscopy for TUNEL assay
RAW 264.7 cells were plated onto the fabricated substrate 
slides (glass, polymer only, or polymer–drug) and grown for 
67 hours at 37 °C with 5% carbon dioxide. Cultures were 
supplemented with an additional 10% FBS every 24 hours 
to prevent serum starvation. The TUNEL based ApopTag® 
Plus Fluorescein In Situ Apoptosis Detection Kit (Chemicon 
International, Temecula, CA) was used for cell staining to 
detect apoptosis positive cells following the manufacturer’s 
protocol. Propidium iodide was used for counterstain. Cells 
were imaged using a Leica inverted microscope Confocal 
Laser Scanning System and a 40x oil immersion objective. 
Images were obtained using the Leica Confocal imaging 
software. Fluorescein was excited at a wavelength of 494 nm International Journal of Nanomedicine 2008:3(4) 428
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and emission was monitored at 518 nm. Propidium iodide 
was excited at a wavelength of 536 nm and emission was 
monitored at 617 nm.
Results
Anti-inﬂ  ammatory-chemotherapy 
copolymeric nanoﬁ  lm fabrication
Mixtures of copolymers with the drugs Dex and Dox were 
characterized via Langmuir isotherms and copolymer–
Dex–Dox thin ﬁ  lms were fabricated via Langmuir–Blodgett 
deposition. Figure 2 shows the compression isotherms for 
the PMOXA–PDMS–PMOXA triblock copolymer nanoﬁ  lm 
alone or mixed with Dox, Dex, or both Dex and Dox. The 
variations in the isotherms of the copolymer–drug mixtures 
demonstrate that the readings were responsive to varied drug 
amounts and that this mixture was able to generate high sur-
face pressure readings indicative of ﬁ  lm formation. These 
graphs show that drug integration into the copolymer ﬁ  lm 
occurs due to changes between compression phase transitions 
and maximum collapse pressures. These graphs are similar to 
the variations in surface pressure that have been seen when 
drugs have been incorporated into a copolymer thin ﬁ  lm at the 
air-water interface using Langmuir–Blodgett (Pierstorff et al 
2008). Copolymer ﬁ  lms mixed with either Dex or Dox alone 
have been previously characterized and demonstrate incorpo-
ration of either drug into the copolymer matrix (Chow et al 
2008; Pierstorff et al 2008). Interestingly, when both Dox and 
Dex are mixed with the copolymer nanoﬁ  lm and compressed, 
the isotherm completely overlaps that of copolymer and Dex 
alone. Thus, even though the copolymer–Dox mixture alone 
has a shift in the isotherm (Figure 2; Pierstorff et al 2008), it 
appears that this is masked or overwhelmed by the presence 
of Dex in the mixture as well. While the mechanism driving 
this observation was unclear, Dox activity assays revealed 
its incorporation into the copolymer nanoﬁ  lm.
Polymer–dexamethasone-induced 
suppression of inﬂ  ammatory gene 
expression
Dex incorporation and release from the deposited polymer–
Dex–Dox thin ﬁ  lms was monitored via the inﬂ  ammation 
of cells grown on the polymer–Dex–Dox ﬁ  lms with LPS 
followed by quantitative RT-PCR trials to examine the 
Dex-mediated suppression of IL-6 and TNFα expression 
(Figures 3A and 3B). IL-6 gene expression was signiﬁ  cantly 
lower in cells grown on polymer–Dex–Dox ﬁ  lms, suggesting 
that the drug was both present in the ﬁ  lm and accessible to 
the cells frown on the slide (Figure 3A). As a control for 
Dex mediated cellular inﬂ  ammation suppression, aqueous 
Dex was added directly to the media of cells inﬂ  amed with 
LPS. The reduction in IL-6 expression was comparable in 
cells grown on the polymer–Dex–Dox ﬁ  lms (Figure 3A). 
Furthermore, the TNFα locus was used as an additional 
demonstration of inﬂ  ammation reduction in cells grown on 
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Figure 2 Conﬁ  rmation of doxorubicin hydrochloride and dexamethasone drug incorporation into the PMOXA–PDMS–PMOXA triblock copolymer was performed via 
monitoring of surface pressure changes of fabricated Langmuir ﬁ  lms. Subsequent drug activity trials conﬁ  rmed the functionality of deposited hybrid material.International Journal of Nanomedicine 2008:3(4) 429
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Figure 3 A) RT-PCR analysis of IL-6 gene expression was done following macrophage incubation with the polymer–Dex–Dox nanoﬁ  lms. Gene expression assays with aqueous 
Dex added were conducted as a control for Dex activity. Results indicated the incorporation of Dex into the copolymer–Dex–Dox thin ﬁ  lm and a potent drug releasing 
activity as shown through a substantial reduction in inﬂ  ammatory gene expression. B) In addition, RT-PCR analysis of TNFα gene expression was done following macrophage 
incubation with the polymer–Dex–Dox nanoﬁ  lms. Gene expression assays with aqueous Dex added were conducted as a control for Dex activity. Results further indicated the 
incorporation of Dex into the copolymer–Dex–Dox thin ﬁ  lm and a potent drug releasing activity as shown through a substantial reduction in inﬂ  ammatory gene expression. The 
broad suppression of inﬂ  ammatory gene expression demonstrates an efﬁ  cient hybrid nanoﬁ  lm system for an active drug delivery interface. Data was acquired and responses 
were observed from a minimum of three trials.International Journal of Nanomedicine 2008:3(4) 430
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polymer–Dex–Dox. As with IL-6, there was signiﬁ  cant and 
comparable reduction of TNFα expression in cells grown on 
the polymer–Dex–Dox ﬁ  lms (Figure 3B).
Doxorubicin-copolymer driven cellular 
apoptosis
Conﬁ  rmation of copolymer-mediated Dox incorporation 
and release from polymer–Dex–Dox was also performed 
using RAW 264.7 macrophage cells. Studies examining 
Dox-induced DNA fragmentation as well as apoptosis 
induction and cellular viability via confocal microscopy 
(TUNEL assays) were used to monitor the onset of apoptosis. 
DNA fragmentation is an indication of cellular apoptosis 
(Hassan et al 2005). Analysis of polymer–Dex–Dox induced 
apoptosis was performed via the electrophoresis of cellular 
DNA and looking for the accumulation of the characteristic 
laddering of fragmented DNA. The polymer–Dex–Dox 
hybrids generated a very pronounced DNA fragmentation 
pattern comparable to that of polymer–Dox hybrids previ-
ously characterized, thus demonstrating that Dox was both 
present in the copolymer ﬁ  lms and accessible to the cells 
grown on the ﬁ  lms (Figure 4). Both the glass-only and the 
Figure 4 DNA fragmentation assays revealed the preserved functionality of Dox in polymer–Dex–Dox nanoﬁ  lms. Lane 1 is a DNA marker. Lane 2 represents the control 
without polymer or drug. Lane 3 represents the culturing of macrophages atop polymer only substrates. Lane 4 represents the polymer–Dox hybrid activity as shown through 
the clear fragmentation of DNA. Lane 5 represents the polymer–Dex–Dox hybrid activity as shown through the clear fragmentation of DNA. Controlled and localized che-
motherapeutic release would signiﬁ  cantly enhance the efﬁ  cacy of cancer treatment via the reduction of systemic toxicity due to systemic administration. The lack of DNA 
fragmentation or cell death of cells grown on the copolymer substrate highlight the biocompatible properties of the copolymer.International Journal of Nanomedicine 2008:3(4) 431
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polymer-only control conditions revealed the absence of 
DNA laddering, thus demonstrating the induction of apop-
tosis from the polymer–Dex–Dox hybrids as Dox-dependent 
and providing further supporting evidence for the biocompat-
ibility of the copolymer nanoﬁ  lm.
Confocal microscopy also revealed the impact of 
Dox elution from the copolymeric nanoﬁ  lm upon cellular 
morphology and apoptosis progression via a TUNEL 
based staining assay (Figure 5). The polymer–Dex–Dox 
and polymer–Dox hybrids produced enlarged cellular 
morphologies that were indicative of pre-apoptotic cells. 
Glass-only and polymer-only control slides produced cells with 
unaltered morphologies. In addition, though the same number 
of cells were seeded per slide, signiﬁ  cantly fewer cells grew 
and propagated on the polymer–Dex–Dox and polymer–Dox 
hybrid slides. When staining for double stranded breaks indica-
tive of apoptosis progression, none was seen in cells grown on 
glass or polymer only slides. However, in both the polymer–
Dox and the polymer–Dex–Dox slides, an accumulation of 
apoptotic cells is observed (Figure 5). This is detected both 
Glass
Polymer
Polymer +
Dox
Polymer +
DexDox
Propidium Iodide TUNEL Overlay
Figure 5 Microscopy Dox impact upon cellular proliferation and morphology was demonstrated via confocal microscopy. Macrophages cultured atop glass or polymer only 
substrates produced highly conﬂ  uent growth. Macrophages cultured atop polymer–Dox and polymer–Dex–Dox nanoﬁ  lm hybrids generated decrease cell conﬂ  uency, enlarged, 
preapoptotic cells, as well as shrunken apoptotic cells due to Dox-induced cell death/apoptosis. TUNEL assays demonstrate the progression of cells grown on polymer–Dox 
and polymer–Dex–Dox nanoﬁ  lm hybrids to apoptosis.
Notes: Magniﬁ  cation: 40X, Leica inverted microscope Confocal Laser Scanning System.International Journal of Nanomedicine 2008:3(4) 432
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by the TUNEL stain accumulation and also the shrinking of 
the apoptotic cells from their pre-apoptotic morphology. Once 
again this demonstrates a potent Dox dependent apoptosis 
inducing functionality to the polymer–Dex–Dox ﬁ  lms.
Discussion and conclusions
As was previously described, PMOXA-PDMS-PMOXA block 
polymer based hybrid ﬁ  lms can act as platforms for local-
ized drug elution (eg, from an implant surface) and be used 
as an alternative to systemic drug release (Chow et al 2008; 
Pierstorff et al 2008). As such, equivalent, or even greater, drug 
administration at the desired site can be achieved using this 
technology than from widespread drug delivery, thus increasing 
efﬁ  cacy of treatment. In this study, a dual-therapeutic eluting 
polymer-hybrid ﬁ  lm was constructed that releases functional 
anti-inﬂ  ammatory (Dex) and anti-cancer drugs (Dox). This 
suggests that the triblock copolymer can provide the both thera-
peutics to a location from a single device and could be a more 
effective drug delivery strategy than systemic/solution-based 
elution. The Langmuir-Blodgett methodology is an excellent 
proof of concept for the co-deposition of multiple drugs and 
copolymer at the air–water interface. Continued work will 
investigate higher throughput deposition methods.
It is vital to incorporate anti-inﬂ  ammatory functionality to 
any drug eluting implantable medical device. The decrease in 
inﬂ  ammation will counteract the foreign body response and 
increase the lifespan of the implanted device and, in the case of 
an anti-cancer therapeutic drug eluting coating, prolong the time 
of effective drug release from the device. In addition, increases 
in IL-6 expression can counteract or have negative impacts on 
chemotherapy. For example, chronic inﬂ  ammation can cause 
apoptosis in various tissues and even induce the onset of cancer 
(Hjelstrom 2001; Palapattu et al 2005), thus, not only increasing 
the danger of implantation, but also negating the anti-cancer 
properties of a chemotherapy eluting device. IL-6 has also 
been implicated in prostate cancer progression via multiple 
signaling pathways (Giri et al 2001; Park et al 2003), tumor 
angiogenesis and inﬂ  ammation (Hirano et al 1997; Taga and 
Kishimoto 1997; Giri et al 2001; Willenberg et al 2002), tumor 
progression and pathogenesis (Siegall et al 1990). As such, both 
the absence of inﬂ  ammation from cellular–nanopolymer inter-
action and the incorporation of anti-inﬂ  ammatory drugs from 
its matrix make the polymer-hybrid ﬁ  lms extremely promising 
towards clinical and applied nanomedicine.
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